Moreover, lung adenocarcinoma patients with higher coexpression of CD109 and YAP showed worse overall and disease-specific survival probabilities (Figure 6C), underpinning the potential role of CD109 possibly serving as prognostic and therapeutic targets for lung adenocarcinoma patients. This evidence concerns the gene CD109 and lung adenocarcinoma.